HUM-233

HUM-233 is a **synthetic small-molecule cannabigerol derivative** and the **maleate salt form of HUM-234** being developed by **ETHZilla** and **The Hebrew University of Jerusalem** for **inflammatory conditions and pain**. It has been described as a **cannabinoid receptor modulator** and, in preclinical studies, has shown **anti-inflammatory** and **analgesic** activity. The compound is chemically synthesized from **monomethoxy cannabigerol** and is part of a series of novel CBG derivatives that includes HUM-223, HUM-233, and HUM-234. Development appears to be **preclinical / in development**, with mechanism and target specificity not yet fully characterized publicly.

Other names

HUM-234 maleateHUM234 maleateHUM 234 maleatemaleate salt form of HUM-234